FDA delays decision on Agios drug in thalassemia over liver safetynews2025-09-04T13:48:24+00:00September 4th, 2025|Endpoints News|
CDER and CBER offer new submission program for rare disease gene therapiesnews2025-09-03T15:41:24+00:00September 3rd, 2025|Endpoints News|
Prasad spells out new thinking on vaccine development in Covid-19 memosnews2025-09-02T19:28:50+00:00September 2nd, 2025|Endpoints News|
RFK Jr. critic Paul Offit dismissed from FDA’s vaccine advisory committeenews2025-09-02T17:41:58+00:00September 2nd, 2025|Endpoints News|
FDA approves BTK inhibitor that’s key to Sanofi’s immunology strategynews2025-08-29T22:01:01+00:00August 29th, 2025|Endpoints News|
FDA approves Eisai and Biogen’s subcutaneous Leqembinews2025-08-29T21:00:40+00:00August 29th, 2025|Endpoints News|
FDA takes ‘important step’ toward non-invasive tests for MASH trialsnews2025-08-28T19:25:33+00:00August 28th, 2025|Endpoints News|
Prasad explains why FDA revoked Pfizer’s Covid vaccine EUA for childrennews2025-08-28T13:10:59+00:00August 28th, 2025|Endpoints News|
FDA again rejects Outlook Therapeutics’ version of Avastin for wet AMDnews2025-08-28T11:55:50+00:00August 28th, 2025|Endpoints News|
FDA talks limitations, potential for cancer registriesnews2025-08-27T18:11:55+00:00August 27th, 2025|Endpoints News|
